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Combination strategies
Abstract
The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine
kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors have been
developed. Several other signal transduction pathways have been found to be constitutively active or mutated in
other subsets of melanoma tumors that are potentially targetable with new agents. Among these, NFB is another
pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-
B activation appears to be a very promising option for anti-cancer therapies.
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Introduction
Melanoma is considered the most aggressive form of
skin cancer, derived from activated or genetically altered
epidermal melanocytes. In recent years, an alarming
increase in incidence rates, higher than that observed
for all other types of malignant tumors, has been regis-
tered [1].
Human malignant melanoma is a highly metastatic
cancer that is markedly resistant to conventional ther-
apy, with dacarbazine or temozolomide (TMZ); indeed,
the best single agent activity presents a response rate of
only 15-30% and a median duration of response of few
months [2]. For its biological complexity and clinical dif-
ficulty of management, melanoma is considered a thorn
in oncology’s flesh. Recent achievements in the under-
standing of its molecular complexity and biology has
resulted in important improvements in its therapeutic
management. Still, further insights are needed.
Recent studies have focused on various molecular
levels to identify key factors involved in the induction
and progression of melanoma.
The RAS/MAP kinase pathway has attracted attention
because activating mutations of the BRAF serine/threo-
nine kinase has been detected in more than 50% of
melanomas; in particular, the most common BRAF
mutation (nearly, 90% of cases) is the T1799A point
mutation in exon 15 within the kinase domain, in which
a T ® A transversion converts glutamic acid for valine
at the 600 position of the amino acid sequence
(BRAFV600E) and constitutively activates the protein.
Oncogenic activation of BRAF may drive the positive
control of cell cycle progression, cyclin-D1 mediated [3].
Other mutations occur in NRAS (present in 15%
across all types of melanoma), MEK1, MEK2 as well as
in c-KIT, encoding for an upstream growth factor recep-
tor. The latter has been shown to be amplified or
mutated in some cases of melanomas and in particular
the prevalence is closer to 1% in the Caucasian popula-
tion, specifically those that develop on body sites with
little UV exposure. Activation of this tyrosine kinase
results in the stimulation of the MAPK and PI3K-AKT
pathways, producing both proliferative and survival
advantages [4].
The study and the discovery of DNA mutations in
melanoma provides new tools for controlling the dis-
ease: indeed, it has been possible to study and use drugs
directed to the inactivation of proteins erroneously acti-
vated during melanoma pathogenesis [5].
Sorafenib was tested in melanoma as a BRAF inhibitor
in combination with chemotherapy in both first and sec-
ond line phase 3 trials, but failed to provide an improve-
ment in outcome compared to chemotherapy alone
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[6,7]. Presumably, this was due to a suboptimal ability of
Sorafenib to inhibit BRAF and lack of patient selection
for BRAF mutations at the time the studies were
conducted.
More selective and potent BRAF inhibitors have been
developed. Vemurafenib is the first of a new generation
of BRAF inhibitors that showed very promising activity
in a phase 1 study, subsequently confirmed in phase 2
and 3 studies, among BRAF mutation positive patients.
The phase III study comparing vemurafenib to dacarba-
zine showed a relative reduction of 63% in the risk of
death and of 74% in the risk of either death or disease
progression [8].
Another innovative approach was based on the use of
monoclonal antibodies (Mabs) that specifically target
CTLA-4 (cytotoxic T lymphocyte-associated antigen 4).
CTLA-4 signaling switches off T-cell activation and
induces immune tolerance. Inhibiting CTLA-4 increases
and prolongs the antitumor T-cell response. Tremelimu-
mab and ipilimumab were the most important anti-
CTLA-4 Mabs used in the treatment of advanced mela-
noma. Although tremelimumab failed to improve out-
come in the phase 3 setting [9], ipilimumab has been
successful approved for the treatment of metastatic mel-
anoma. Two phase 3 trials, one in the second line and
another in first line, have shown improvement in survi-
val with the use of this latter agent; durable responses
have been shown with manageable toxicities [10].
Actually, these new therapies are under investigation
for their combination with treatments aimed at blocking
other key molecular pathways involved in the progres-
sion of melanoma [11].
Several other signal transduction pathways have been
found to be constitutively active or mutated in other sub-
sets of melanoma tumors that are potentially targetable
with new agents. Among these, NFB is another pathway
that melanoma tumors use to achieve survival, prolifera-
tion, resistance to apoptosis and metastasis. In fact, it has
been demonstrated that upregulation of the NF-B levels
is involved in both the progression of melanoma [12] and
the increase of its metastatic potential [13].
Therefore, inhibition of NF-B activation appears to
be a promising option for anti-cancer therapies.
NF-B transcription factor: its role in cellular life
NF-B is a complex protein that acts as a transcriptional
factor and regulates the transcription of several genes
involved in many critical pathways. It was identified
many years ago as a regulator of B cell-specific gene
expression; recently, studies have highlighted that it is a
member of the structurally-related eukaryotic transcrip-
tion factors family NF-B/Rel that regulates the expres-
sion of many inducible genes involved in the control of
a large number of normal cellular and organismal
processes [14]. Specific NF-B binding sites character-
ized by the consensus sequence: gggRNNYYCC (R =
purine Y = pyrimidin), have been identified in promo-
ters and enhancers of a great number of genes. This
family is composed by related, evolutionarily conserved
DNA-binding proteins consisting of p50, p52, RelA/p65,
c-rel and RelB. The NF-B proteins share an approxi-
mately 300 amino acid N-terminal domain called the
Rel homology (RH) domain containing important
sequences for binding DNA or inhibitor of NF-B (IB)
as well as sites of dimerization. However, they differ in
their C-terminal domain in that RelA, RelB and c-Rel
exhibit transactivating functions, while p100 and p105
contain inhibitory domains. In fact, NF-B1/p105 and
NF-B2/p100 are the inactive precursors of the p50 and
p52 proteins, respectively. In an unstimulated state,
these proteins are localized into the cytoplasm. Proteoly-
tic processing removes the C-terminal inhibitory
domains, allowing the resulting proteins to enter the
nucleus. p50 and p52 usually form homodimers or het-
erodimers with one of the three proteins that has a
transactivation domain. NF-B proteins are sequestered
in the cytoplasmic compartment, associated with mem-
bers of the IkB family (IkBa, IkBb and IkBe). Their acti-
vation is the result of a variety of different stimuli,
including those activating some membrane receptors [B
cell receptor (BCR), tumor necrosis factor receptors
(TNFR)] and several extracellular stimuli (inflammatory
cytokines, viral and bacterial infections, oxidative and
DNA-damaging agents, UV light and osmotic shock)
[15].
Activation of these signaling cascades is involved into
phosphorylation of two critical serine residues in IkB
proteins. Such a modification triggers their ubiquitina-
tion and destruction via proteasome degradation
machinery. As a consequence, free NF-B translocates
to the nucleus and activates transcription in multiple
genes involved in pathways controlling immune and
inflammatory responses, developmental processes, cellu-
lar growth and apoptosis [16].
This event depends on activation of an upstream mul-
timeric IKK complex, formed by two highly homologous
kinases, IKKa and IKKb, and one non-enzymatic pro-
tein, IKKg or NEMO (NF-B essential modulator) and a
newly identified protein ELKS.
NEMO is a regulatory component, considered as
indispensable for the formation of the IKK complex
through a bound to the specific carboxyl-terminally
conserved residues (termed NEMO binding domain;
NBD) of both IKKa and IKKb. The trimeric complex
phosphorylates IΒ and induces its proteasomal degra-
dation via ubiquitination. NF-B is then capable to
migrate into the nucleus and activate the transcription
of target genes. This classical pathway mostly involving
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p50:RelA and p50:c-Rel dimers strongly depends on
IKKb activity.
Activation of trimeric IKK complex is triggered by
microbial and viral infections or proinflammatory sti-
muli and is responsible, under certain conditions, for
inhibition of apoptosis as well as inflammatory and
innate immune responses [17]. In addition to the classi-
cal pathway, a non-canonical alternative pathway exists,
that does not depend on the interaction of IKKb and
NEMO but uniquely on the specific activation of a
homodimer of IKKa, which is activated by the upstream
kinase NIK and members of the TNF cytokine family
(BAFF). This pathway leads to selective activation of
NF-B2/p100 precursor protein that resides in the cyto-
plasm; this event leads to the formation of a heterodi-
mer with RelB that traslocates in the nucleus and
activates the transcription of important genes involved
in cell survival [18].
Constitutive activation of NF-B in melanoma
NF-B has pleiotropic effects in the surrounding envir-
onment, but three are its essential roles.
It is involved into the proinflammatory response: a
first line of defense against infectious diseases and cellu-
lar stress and comprises immune, inflammatory, and
acute phase responses.
NF-B is also a major anti-apoptopic factor, inducing
the trascription of several anti-apoptotic proteins, such
as Bcl-XL, tumor necrosis factor receptor-associated fac-
tor 1 and 2 (TRAF1 and TRAF2, respectively), and the
inhibitor-of-apoptosis (IAP) protein 1 and 2 (c-IAP1
and c-IAP2, respectively). Therefore, NF-B curbs the
activities of the caspase family of enzymes, which are
central in most apoptotic processes.
Finally, NF-B promotes cell growth: activated NF-B
enhances the expression of cyclin D1 that is an impor-
tant regulator of cell cycle progression.
Given the breadth of biological mechanisms associated
with NF-B, it is not surprising that NF-B pathway is
altered in several malignancies.
In melanoma cells, recent studies have highlighted that
some components of NF-B family, such as p50 and p65/
RelA proteins, are overexpressed in the nuclei of dysplastic
nevi and melanoma cells compared to those of normal
nevi and healthy melanocytes, respectively [19].
These phenomena are more closely associated with an
increased activity of IKK, resulting in more rapid degra-
dation of IB, nuclear localization of NF-B, and
enhanced transactivating capacity of the NF-B com-
plex. In fact, the equilibrium between IBa degradation
and resynthesis has been found altered in Hs294T mela-
noma cells, with a shift of the process toward the first
event (degradation) leading to constitutive nuclear trans-
location and activation of NF-B [20].
Other data show that a hyperactivation of NF-B can
be also caused by an increased expression of other fac-
tors involved indirectly in NF-B pathway. Recent stu-
dies on the gene expression profile of melanoma cells
have shown an increased expression of Osteopontin
(OPN) [21], a secreted glycophosphoprotein that induces
NF-B activation through enhancement of the IKK
activity based on phosphorylation and degradation of
IBa [22]. Indeed, OPN induces Akt phosphorylation
and, in turn, phosphorylated Akt binds to IKKa/b and
activates IKK complex [22].
Mutational activation of BRAF, common in human
melanomas, has been also associated with an enhanced
IKK activity and a concomitant increase in the rate of
IBa ubiquitination and its subsequent degradation.
This process overall entails a constitutive induction of
NF-B activity and an increased survival of melanoma
cells [23]. Combination of these data with others
reported in literature strongly suggests that the
enhanced activation of NF-B may be due to deregula-
tions occurring in upstream signaling pathways such as
RAS/RAF, PI3K/Akt and NIK [24]. In transformed cells,
these alterations lead to a consequent increase in prolif-
eration rates and resistance to apoptosis; moreover, acti-
vation of NF-B may enhance expression of
proinflammatory mediators, leading to acute inflamma-
tory injury in multiple organs and development of dys-
function as well as cancer in several anatomical districts.
Inhibitors of NF-B as therapeutic option in melanoma
All findings presented above suggest that inhibition of
NF-B can be used as a strategy to effectively interfere
with the pathogenesis and/or progression of melanoma.
However, the multiplicity of actions of NF-B could
have the drawback that this type of therapy might entail
disadvantageous effects: a reduction of the NF-B acti-
vation could lead to an impairment of either the migra-
tion of natural killer (NK) cells or the concentration of
the tumor infiltrating lymphocytes (TILS) and dendritic
cells into the developing tumor. All these effects might
reduce or abolish the immune response against the
tumor. Recent studies with substances that inhibit the
activity of NF-B have hypothesized that these
unwanted biological effects in tumor tissues may be
apparently overcome by a much stronger enhancement
of apoptosis into the tumor cells [25]. Several molecules
targeting different parts of the NFB pathway are here
discussed.
Bortezomib
Recent studies have shown that proteasome inhibitors
represent a new class of anticancer agents by inhibiting
degradation of cell cycle regulatory proteins, such as
cyclin-dependent kinase inhibitors and IB protein.
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Since NF-B activity is regulated by phosphorylation
and proteasome-dependent degradation of its inhibitor
IB, the use of a proteasome inhibitor may represent an
effective approach into the treatment of melanoma with
constitutive activation of NF-B.
Bortezomib (Velcade, previously known as PS-341), a
proteasome inhibitor, was one of the first compounds
used to inhibit the function of NF-B. Bortezomib is an
anticancer agent that is not subject to classic MDR-
dependent inactivation; it has a wide spectrum of
actions in hematologic and solid tumors, including mul-
tiple myeloma as well as lung, breast, prostate, pancrea-
tic, and head-neck carcinomas [26]. In melanoma,
Bortezomib inhibits the cell growth in vitro , even at
low drug concentrations (range of 0.1-10 nM) [27]. This
compound was subsequently tested in combination with
temozolomide, a conventional chemotherapeutic agent,
resulting in a more prominent inhibition of the mela-
noma cell proliferation [27]. This compound was finally
tested in vivo in mouse models, either alone or in com-
bination with temozolomide. A markedly reduction of
the tumor growth was observed when bortezomib was
administered as single agent; more strikingly, animals
receiving bortezomib in combination with temozolomide
achieved complete remission of palpable tumors after
only 30 days of therapy [27].
Recently, a phase I safety/dose-finding study combin-
ing Bortezomib with temozolomide in 17 patients with
advanced metastatic melanoma was reported [28]. A
phase 2 combination dose of Bortezomib (1.3 mg/m2 on
d1, 4, 8, and 11 q 21 days) and TMZ (75 mg/m2 daily
for 6 out of 9 weeks) was established. Side effects
included grade 3 and 4 fatigue, nausea and vomiting,
diarrhea, neuropathy, and rash [28].
The efficacy of Bortezomib was recently explored in
another 2-stage phase 2 clinical trial in combination
with other chemotherapeutic agents, including paclitaxel
(PAC) and carboplatin (CBDCA) in patients with
advanced solid tumors. This study has shown limited
clinical advantage and significant toxicity (severe hema-
tologic toxicities, such as neutropenia and leukopenia;
severe pulmonary embolism); for these reasons this trial
did not proceed to second-stage accrual [29].
Curcumin
Another compound that has been shown to exert
numerous effects - primarily antioxidant, anti-inflamma-
tory, antiproliferative, and pro-apoptotic activities
against a variety of tumors in vitro is curcumin (diferu-
loylmethane), a polyphenol with demonstrated antican-
cer properties, extracted from the rhizome of the plant
Curcuma longa which represents a yellow pigment used
as a food additive isolated from the spice turmeric
(curry powder).
The antiproliferative and proapoptotic effects are asso-
ciated with the ability of curcumin to downregulate the
levels of some transcription factors (such as NF-B, AP-
1, Egr-1), growth factors receptors (such as epidermal
growth factor receptor [EGF] and human EGF receptor
2), other signaling proteins (such as COX2, LOX, NOS,
MMP-9, uPA, TNF, chemokines, cell surface adhesion
molecules and cyclin D) and other tyrosine kinases and
serine/threonine kinases protein [30]. Among others, one
of the major anticancer effects of curcumin is due to its
capability of triggering apoptosis in tumour cells through
modulation of the NF-B and the PI3K/Akt mediated
signalling pathways [31]. These evidence suggest that
curcumin may modulate pathways which contribute to
chronic inflammation underlying tumorigenesis or path-
ways directly involved in tumorigenesis.
For these properties, curcumin was used in experi-
ments based on melanoma cells as in vitro and in vivo
models. Using a MTT proliferation assay, melanoma cell
lines treated with curcumin for 72-96 hours were signifi-
cantly inhibited in cell growth and survival, in an irre-
versible manner [32]. Furthermore, curcumin was found
to induce a dose-dependent increase in apoptosis among
human melanoma cell lines [32].
In other studies, curcumin was demonstrated to be
cytotoxic in vitro for B16-R melanoma cells resistant to
treatment with doxorubicin in monolayer cultures; such
a cytotoxic effect has been related to the induction of
programmed cell death [33]. In 3-D cultures of B16-R
cells (called spheroids) - that are more resembling in vivo
solid tumors, higher doses of the compound are needed
in order to achieve the same antiproliferative effects since
the spheroids cells are more resistant to the cytotoxicity
induced by curcumin. To test curcumin’s antitumoral
effects in vivo, a first group of mice carrying melanoma
lesions were pretreated with an immune therapy that
contained proteins derived from the melanoma cells,
while another group was treated with curcumin, and a
third group received both treatments. Despite each treat-
ment alone showed a poor response, the combination of
them resulted in a substantial inhibition of tumor growth
and a considerable improvement of the immune reaction
against tumor lesions [33]. When survival was evaluated,
the simultaneous administration of the immune therapy
and curcumin was found to markedly improve median
survival (which has been estimated to be increased by
roughly 83 percent as compared to untreated mice using
a combined treatment) [33].
In conclusion, curcumin could be used as an adjuvant
compound in the treatment of melanoma. The impor-
tance of curcumin also lies in the fact that this drug
appears to reduce the metastatic potential of melanoma,
which is the main cause of death in patients. Treatment
of highly metastatic murine melanoma B16F10 cells
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with curcumin (15 μM) for 15 days significantly inhib-
ited matrixmetalloproteinase-2 (MMP-2) activity, which
has been described to promote cell motility and metas-
tasis formation, thus increasing the metastatic potential
[34]. Expression of MMP-2 did not return to control
levels even after several weeks form drug withdrawal
[34]. Reduction of MMP-2 activity has been therefore
indicated as an important mechanism by which curcu-
min exert its anti-metastatic property [34]. Recently, a
new curcumin-related biphenyl structure (a,ß-unsatu-
rated ketone D6) with more effective and selective anti-
proliferative and proapoptotic activity on both
melanoma cell lines and in vivo melanomas has been
described [35].
So far, no apparent side effects have been reported in
literature when using curcumin-based treatments.
Increased body temperature represents the most com-
mon side effect during treatment with high doses of
curcumin. However, this issue remains controversial; a
study performed at the University of Michigan showed
no curcumin toxicity at doses up to 6 grams [36],
whereas a recent trial based on curcumin given in com-
bination with gemcitabine in patients with advanced
pancreatic cancer reported some important side effects,
such as intractable abdominal fullness or pain and other
abdominal complaints [37].
Selective inhibitors of NF-B pathway
The above-mentioned treatments include substances
that block, in addition to the NF-B pathway, other
molecular pathways, because their action is not directed
solely and specifically to NF-B but to a broad spectrum
of proteins. The nonspecific action of these drugs does
not allow to fully understand the role of NF-B in can-
cer and its real value as a therapeutic target. On this
regard, the attention has recently shifted to possible
agents that could more selectively target the NF-B
pathway.
A compound that more directly targets the NF-B
pathway is BMS-345541 (4(2’-aminoethyl) amino-1,8-
dimethylimidazo(1,2-a)quinoxaline). It was identified as
a selective inhibitor of the catalytic subunit of IKK that
binds to an allosteric site of the enzyme [38]. The activ-
ity of this compound was tested in vitro on three mela-
noma cell lines that have high levels of constitutively
active IKK. The treatment induces a concentration-
dependent inhibition of melanoma cell proliferation and
apoptotic features, such as obvious nuclear condensation
and DNA fragmentation. Successively BMS-345541 was
tested in melanoma-bearing mice observing a dose-
dependent suppression of tumor growth with good tol-
erance [39].
Besides the BMS-345541, several compounds are actu-
ally at different stages of development. Among others, a
significant inhibitory activity has been recently docu-
mented for the NBD (NEMO-binding domain) peptide
[40]. This is a short peptide with high affinity to the
IKK complex and it is fused with a sequence derived
from the Drosophila antennapedia homeodomain that
mediates membrane translocation. In more details, the
NBD is a hexapeptide sequence (Leu-Asp-Trp-Ser-Trp-
Leu) within the extreme carboxyl-terminal region of
IKKa and IKKb that binds an NH2-terminal a-helical
region of NEMO [41]. The interaction between NEMO
and IKKa/b is crucial for the activation of the IKK com-
plex and the subsequent activation of NF-B.
This last evidence has led to the hypothesis of using a
sequence that mimics the NBD region in the treatment
of pathologies in which NF-B plays an important role.
For this purpose, a cell-permeable synthetic NBD pep-
tide was used in inflammatory pathologies, such as
inflammatory arthritis and synovial inflammation with
good results also confirmed in animal models of inflam-
mation [42]. The molecular mechanism underlying the
activity of the NBD peptide is here summarized. The
NBD peptide inhibits the activation of NF-B by target-
ing the NBD-NEMO interaction; when IKKa and IKKb
are bound to the NBD peptide, they cannot bind to
NEMO and thus the formation and function of the IKK
complex is blocked (Figure 1).
Recently, our group has conducted a study aimed at
evaluating the efficacy of treatment with the NBD pep-
tide in melanoma cells in vitro. It has been shown that
A375 human melanoma cells, which present high con-
stitutive levels of NF-B, treated with different concen-
trations of synthetic NBD peptide, undergo a growth
arrest in a dose-dependent manner; this effect is accom-
panied and strengthened by the impaired ability of NF-
B to bind to DNA [43]. It was also demonstrated that
the reduction of cell proliferation induced by the NBD
peptide is due to a significant increase of apoptosis, as
shown by the presence of the cleaved form of poly-
(ADP ribose)-polymerase (PARP-1) protein, considered
one of the best markers of the apoptotic machinery [43].
All these effects were not detected using a control pep-
tide having a mutation in its consensus sequence [43].
These investigations have been then extended to other
nine melanoma cell lines in which the activity of NF-B
resulted strongly reduced following treatment with NBD
(Gentilcore et al., unpublished observations). Although
not all the nine cell lines have the same baseline expres-
sion of NF-B, the NBD peptide was able to induce acti-
vation of the pro-apoptotic caspase-3 protein in the
entire series of melanoma cell lines with a quite homo-
geneous distribution of the activation levels among the
different cell lines (Gentilcore et al., unpublished obser-
vations.). Anyway, all these data demonstrate how NF-
B can be used as a specific target in the treatment of
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melanoma. Furthermore, it is worth extending the use of
synthetic peptide NBD in in vivo studies based on ani-
mal models and, finally, in clinical trials among humans.
Conclusions
NF-B signaling is deregulated in many tumor types,
resulting in aberrant expression and/or activation of NF-
B transcriptional complexes. Its role in the regulation
of apoptosis, tumor angiogenesis and proliferation, as
well as tumor cell invasion and metastasis indicates that
this transcription factor may become a therapeutic tar-
get in the treatment of many human cancers, including
melanoma, in which the levels of NF-B is constitutively
increased.
The existence of several NF-B inhibitors may result
in a significant improvement of the anti-tumor tools
against melanoma, both in vitro and in vivo. More
importantly, highly specific inhibitors of NF-B may be
used to minimize the pleiotropic effects of nonspecific
inhibitors and to reduce toxicity in vivo. This field of
research is new, with great potentiality, and worth being
exploited in order to provide more and alternative
options for the treatment of melanoma.
Author details
1Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori
Fondazione, G. Pascale, Napoli, Italy. 2Cancer Therapy Evaluation Program,
National Cancer Institute, Bethesda, USA. 3Institute of Biomolecular
Chemistry-CNR, Sassari, Italy.
Figure 1 Canonical and non canonical NF-kB pathways and related drugs inhibition. The canonical pathway induces activation of IkB-
bound NF-B species (such as relA/p50 or cRel/p50) through activation of an upstream multimeric IKK complex, formed by IKKa, IKKb, and IKKg
or NEMO; this activation results in the phosphorylation (P) of IkBa, its ubiquitylation (Ub) and subsequent degradation by the 26S proteasome.
Release of the NF-B complex allows it to relocate to the nucleus. The non canonical pathway depends on activation of IKKa dimers only. Four
drugs that are used to block NF-B pathways with different mechanism are represented. Bortezomib is a proteasome inhibitor that blocks the
degradation of IkBa; curcumin and BMS-345541 inhibit IKK complex formation (both heterodimeric that omodimeric forms); NBD peptide targets
the NBD-NEMO interaction. The first three compounds block both canonical and non canonical signaling, whereas NBD peptide blocks the
canonical pathway only.
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